DefenCath® (taurolidine and heparin) catheter lock solution is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.

Erin Mistry

Erin Mistry is EVP and Chief Commercial Officer, appointed in January 2023. She served as SVP Payer Strategy, Government Affairs and Trade from 2020 to 2022.  She leads the company’s commercial strategy and execution. Erin brings over 15 years of industry experience at the executive level from consulting to in-house executive management. Prior to joining CorMedix, Erin was Vice President of Market Access at Intarcia Therapeutics responsible for pricing, coverage, access, Real world evidence (RWE) and channel strategy for a competitive product in Type 2 Diabetes. Erin was also Senior Managing Director at Syneos Health where she was responsible for the global P&L of the Value Access Practice. In this capacity, Erin consulted on commercial strategy and market access with emerging, mid, and large biopharma across a broad range of therapeutic categories.   Erin holds an undergraduate and Masters degree in Biomechanical Engineering from North Carolina State University.